Cargando…

A modified Delphi study to develop a practical guide for selecting patients with prostate cancer for active surveillance

BACKGROUND: Active surveillance (AS) is a management option for men diagnosed with lower risk prostate cancer. There is wide variation in all aspects of AS internationally, from patient selection to investigations and follow-up intervals, and a lack of clear evidence on the optimal approach to AS. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Merriel, Samuel W. D., Moon, Daniel, Dundee, Phil, Corcoran, Niall, Carroll, Peter, Partin, Alan, Smith, Joseph A., Hamdy, Freddie, Moore, Caroline, Ost, Piet, Costello, Tony
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7863517/
https://www.ncbi.nlm.nih.gov/pubmed/33541309
http://dx.doi.org/10.1186/s12894-021-00789-5
_version_ 1783647510530621440
author Merriel, Samuel W. D.
Moon, Daniel
Dundee, Phil
Corcoran, Niall
Carroll, Peter
Partin, Alan
Smith, Joseph A.
Hamdy, Freddie
Moore, Caroline
Ost, Piet
Costello, Tony
author_facet Merriel, Samuel W. D.
Moon, Daniel
Dundee, Phil
Corcoran, Niall
Carroll, Peter
Partin, Alan
Smith, Joseph A.
Hamdy, Freddie
Moore, Caroline
Ost, Piet
Costello, Tony
author_sort Merriel, Samuel W. D.
collection PubMed
description BACKGROUND: Active surveillance (AS) is a management option for men diagnosed with lower risk prostate cancer. There is wide variation in all aspects of AS internationally, from patient selection to investigations and follow-up intervals, and a lack of clear evidence on the optimal approach to AS. This study aimed to provide guidance for clinicians from an international panel of prostate cancer experts. METHODS: A modified Delphi approach was undertaken, utilising two rounds of online questionnaires followed by a face-to-face workshop. Participants indicated their level of agreement with statements relating to patient selection for AS via online questionnaires on a 7-point Likert scale. Factors not achieving agreement were iteratively developed between the two rounds of questionnaires. Draft statements were presented at the face-to-face workshop for discussion and consensus building. RESULTS: 12 prostate cancer experts (9 urologists, 2 academics, 1 radiation oncologist) participated in this study from a range of geographical regions (4 USA, 4 Europe, 4 Australia). Complete agreement on statements presented to the participants was 29.4% after Round One and 69.0% after Round Two. Following robust discussions at the face-to-face workshop, agreement was reached on the remaining statements. PSA, PSA density, Multiparametric MRI, and systematic biopsy (with or without targeted biopsy) were identified as minimum diagnostic tests required upon which to select patients to recommend AS as a treatment option for prostate cancer. Patient factors and clinical parameters that identified patients appropriate to potentially receive AS were agreed. Genetic and genomic testing was not recommended for use in clinical decision-making regarding AS. CONCLUSIONS: The lack of consistency in the practice of AS for men with lower risk prostate cancer between and within countries was reflected in this modified Delphi study. There are, however, areas of common practice and agreement from which clinicians practicing in the current environment can use to inform their clinical practice to achieve the best outcomes for patients.
format Online
Article
Text
id pubmed-7863517
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-78635172021-02-08 A modified Delphi study to develop a practical guide for selecting patients with prostate cancer for active surveillance Merriel, Samuel W. D. Moon, Daniel Dundee, Phil Corcoran, Niall Carroll, Peter Partin, Alan Smith, Joseph A. Hamdy, Freddie Moore, Caroline Ost, Piet Costello, Tony BMC Urol Research BACKGROUND: Active surveillance (AS) is a management option for men diagnosed with lower risk prostate cancer. There is wide variation in all aspects of AS internationally, from patient selection to investigations and follow-up intervals, and a lack of clear evidence on the optimal approach to AS. This study aimed to provide guidance for clinicians from an international panel of prostate cancer experts. METHODS: A modified Delphi approach was undertaken, utilising two rounds of online questionnaires followed by a face-to-face workshop. Participants indicated their level of agreement with statements relating to patient selection for AS via online questionnaires on a 7-point Likert scale. Factors not achieving agreement were iteratively developed between the two rounds of questionnaires. Draft statements were presented at the face-to-face workshop for discussion and consensus building. RESULTS: 12 prostate cancer experts (9 urologists, 2 academics, 1 radiation oncologist) participated in this study from a range of geographical regions (4 USA, 4 Europe, 4 Australia). Complete agreement on statements presented to the participants was 29.4% after Round One and 69.0% after Round Two. Following robust discussions at the face-to-face workshop, agreement was reached on the remaining statements. PSA, PSA density, Multiparametric MRI, and systematic biopsy (with or without targeted biopsy) were identified as minimum diagnostic tests required upon which to select patients to recommend AS as a treatment option for prostate cancer. Patient factors and clinical parameters that identified patients appropriate to potentially receive AS were agreed. Genetic and genomic testing was not recommended for use in clinical decision-making regarding AS. CONCLUSIONS: The lack of consistency in the practice of AS for men with lower risk prostate cancer between and within countries was reflected in this modified Delphi study. There are, however, areas of common practice and agreement from which clinicians practicing in the current environment can use to inform their clinical practice to achieve the best outcomes for patients. BioMed Central 2021-02-04 /pmc/articles/PMC7863517/ /pubmed/33541309 http://dx.doi.org/10.1186/s12894-021-00789-5 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Merriel, Samuel W. D.
Moon, Daniel
Dundee, Phil
Corcoran, Niall
Carroll, Peter
Partin, Alan
Smith, Joseph A.
Hamdy, Freddie
Moore, Caroline
Ost, Piet
Costello, Tony
A modified Delphi study to develop a practical guide for selecting patients with prostate cancer for active surveillance
title A modified Delphi study to develop a practical guide for selecting patients with prostate cancer for active surveillance
title_full A modified Delphi study to develop a practical guide for selecting patients with prostate cancer for active surveillance
title_fullStr A modified Delphi study to develop a practical guide for selecting patients with prostate cancer for active surveillance
title_full_unstemmed A modified Delphi study to develop a practical guide for selecting patients with prostate cancer for active surveillance
title_short A modified Delphi study to develop a practical guide for selecting patients with prostate cancer for active surveillance
title_sort modified delphi study to develop a practical guide for selecting patients with prostate cancer for active surveillance
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7863517/
https://www.ncbi.nlm.nih.gov/pubmed/33541309
http://dx.doi.org/10.1186/s12894-021-00789-5
work_keys_str_mv AT merrielsamuelwd amodifieddelphistudytodevelopapracticalguideforselectingpatientswithprostatecancerforactivesurveillance
AT moondaniel amodifieddelphistudytodevelopapracticalguideforselectingpatientswithprostatecancerforactivesurveillance
AT dundeephil amodifieddelphistudytodevelopapracticalguideforselectingpatientswithprostatecancerforactivesurveillance
AT corcoranniall amodifieddelphistudytodevelopapracticalguideforselectingpatientswithprostatecancerforactivesurveillance
AT carrollpeter amodifieddelphistudytodevelopapracticalguideforselectingpatientswithprostatecancerforactivesurveillance
AT partinalan amodifieddelphistudytodevelopapracticalguideforselectingpatientswithprostatecancerforactivesurveillance
AT smithjosepha amodifieddelphistudytodevelopapracticalguideforselectingpatientswithprostatecancerforactivesurveillance
AT hamdyfreddie amodifieddelphistudytodevelopapracticalguideforselectingpatientswithprostatecancerforactivesurveillance
AT moorecaroline amodifieddelphistudytodevelopapracticalguideforselectingpatientswithprostatecancerforactivesurveillance
AT ostpiet amodifieddelphistudytodevelopapracticalguideforselectingpatientswithprostatecancerforactivesurveillance
AT costellotony amodifieddelphistudytodevelopapracticalguideforselectingpatientswithprostatecancerforactivesurveillance
AT merrielsamuelwd modifieddelphistudytodevelopapracticalguideforselectingpatientswithprostatecancerforactivesurveillance
AT moondaniel modifieddelphistudytodevelopapracticalguideforselectingpatientswithprostatecancerforactivesurveillance
AT dundeephil modifieddelphistudytodevelopapracticalguideforselectingpatientswithprostatecancerforactivesurveillance
AT corcoranniall modifieddelphistudytodevelopapracticalguideforselectingpatientswithprostatecancerforactivesurveillance
AT carrollpeter modifieddelphistudytodevelopapracticalguideforselectingpatientswithprostatecancerforactivesurveillance
AT partinalan modifieddelphistudytodevelopapracticalguideforselectingpatientswithprostatecancerforactivesurveillance
AT smithjosepha modifieddelphistudytodevelopapracticalguideforselectingpatientswithprostatecancerforactivesurveillance
AT hamdyfreddie modifieddelphistudytodevelopapracticalguideforselectingpatientswithprostatecancerforactivesurveillance
AT moorecaroline modifieddelphistudytodevelopapracticalguideforselectingpatientswithprostatecancerforactivesurveillance
AT ostpiet modifieddelphistudytodevelopapracticalguideforselectingpatientswithprostatecancerforactivesurveillance
AT costellotony modifieddelphistudytodevelopapracticalguideforselectingpatientswithprostatecancerforactivesurveillance